References
- Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet. 2017;390(10105):1873–1887. doi:https://doi.org/10.1016/S0140-6736(17)31072-3.
- Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72(3):e13070. doi:https://doi.org/10.1111/ijcp.13070.
- Pistoia F, Sacco S, Tiseo C, Degan D, et al. The epidemiology of atrial fibrillation and stroke. Cardiol Clin. 2016; 34(2):255–268. doi:https://doi.org/10.1016/j.ccl.2015.12.002.
- Sharma SK, Verma SH. A clinical evaluation of atrial fibrillation in rheumatic heart disease. J Assoc Physicians India. 2015;63(6):22–25.
- Covaceuszach S, Konarev PV, Cassetta A, et al. The conundrum of the high-affinity NGF binding site formation unveiled? Biophys J. 2015;108(3):687–697. doi:https://doi.org/10.1016/j.bpj.2014.11.3485.
- Saygili E, Rana OR, Günzel C, et al. Rate and irregularity of electrical activation during atrial fibrillation affect myocardial NGF expression via different signalling routes. Cell Signal. 2012;24(1):99–105. doi:https://doi.org/10.1016/j.cellsig.2011.08.007.
- The occurrence of valvular atrial fibrillation: Involvement of NGF/TrKA signaling pathway. J Invest Surg. (In press).